Effect of age, family history of prostate cancer, prostate enlargement and seasonality on PSA levels in a contemporary cohort of healthy italian subjects

Angelo Naselli, Vincenzo Fontana, Carlo Introini, Rossana Andreatta, Paolo Puppo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We assessed the joint effect of age at enrolment, age at follow-up, family history of prostate cancer, prostate enlargement and seasonality on prostate-specific antigen (PSA) estimated through log-normal mixed-effects modeling in an Italian cohort of healthy, 45- to 65-year-old subjects over a 4-year period. The median ratio was used as the measure of effect. Median and mean baseline PSA were 0.78 (interquartile range: 0.41-1.50) and 1.27 (95% CI: 1.19-1.35) ng/mL, respectively. A similar median annual increase of 5.7% (95% CI: 4.8%-6.5%) was found for age at enrolment and age at follow-up. Individuals with moderate to severe prostate enlargement had a median PSA ratio of 1.040 (95% CI: 0.919-1.176) and 1.318 (95% CI: 1.128-1.539), respectively. Median ratios of 1.200 (95% CI: 0.026-1.404) and 1.300 (95% CI: 0.915-1.845), respectively, were computed for subjects with only one or more than one prostate-cancer-affected relatives. Regarding seasonality, the highest value was shown in summertime, the lowest in wintertime, and the resulting median ratio was 1.280 (95% CI: 1.117-1.468). Irrespective of age, baseline PSA was in most cases about 1.00 ng/mL with a yearly median variation of about 5% over a 4-year period. Indeed, prostate enlargement, prostate cancer family history and seasonality showed a remarkable impact on PSA measurement. This should be considered when counseling patients with a PSA history.

Original languageEnglish
Pages (from-to)102-107
Number of pages6
JournalInternational Journal of Biological Markers
Volume26
Issue number2
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Healthy Volunteers
Prostate
Counseling
History

Keywords

  • Age
  • Longitudinal study
  • Mixed-effects model
  • Normality
  • Prostate cancer
  • PSA

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Effect of age, family history of prostate cancer, prostate enlargement and seasonality on PSA levels in a contemporary cohort of healthy italian subjects. / Naselli, Angelo; Fontana, Vincenzo; Introini, Carlo; Andreatta, Rossana; Puppo, Paolo.

In: International Journal of Biological Markers, Vol. 26, No. 2, 04.2011, p. 102-107.

Research output: Contribution to journalArticle

@article{6fdb6573185c4c899acc58ada6fa861d,
title = "Effect of age, family history of prostate cancer, prostate enlargement and seasonality on PSA levels in a contemporary cohort of healthy italian subjects",
abstract = "We assessed the joint effect of age at enrolment, age at follow-up, family history of prostate cancer, prostate enlargement and seasonality on prostate-specific antigen (PSA) estimated through log-normal mixed-effects modeling in an Italian cohort of healthy, 45- to 65-year-old subjects over a 4-year period. The median ratio was used as the measure of effect. Median and mean baseline PSA were 0.78 (interquartile range: 0.41-1.50) and 1.27 (95{\%} CI: 1.19-1.35) ng/mL, respectively. A similar median annual increase of 5.7{\%} (95{\%} CI: 4.8{\%}-6.5{\%}) was found for age at enrolment and age at follow-up. Individuals with moderate to severe prostate enlargement had a median PSA ratio of 1.040 (95{\%} CI: 0.919-1.176) and 1.318 (95{\%} CI: 1.128-1.539), respectively. Median ratios of 1.200 (95{\%} CI: 0.026-1.404) and 1.300 (95{\%} CI: 0.915-1.845), respectively, were computed for subjects with only one or more than one prostate-cancer-affected relatives. Regarding seasonality, the highest value was shown in summertime, the lowest in wintertime, and the resulting median ratio was 1.280 (95{\%} CI: 1.117-1.468). Irrespective of age, baseline PSA was in most cases about 1.00 ng/mL with a yearly median variation of about 5{\%} over a 4-year period. Indeed, prostate enlargement, prostate cancer family history and seasonality showed a remarkable impact on PSA measurement. This should be considered when counseling patients with a PSA history.",
keywords = "Age, Longitudinal study, Mixed-effects model, Normality, Prostate cancer, PSA",
author = "Angelo Naselli and Vincenzo Fontana and Carlo Introini and Rossana Andreatta and Paolo Puppo",
year = "2011",
month = "4",
doi = "10.5301/JBM.2011.8316",
language = "English",
volume = "26",
pages = "102--107",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "2",

}

TY - JOUR

T1 - Effect of age, family history of prostate cancer, prostate enlargement and seasonality on PSA levels in a contemporary cohort of healthy italian subjects

AU - Naselli, Angelo

AU - Fontana, Vincenzo

AU - Introini, Carlo

AU - Andreatta, Rossana

AU - Puppo, Paolo

PY - 2011/4

Y1 - 2011/4

N2 - We assessed the joint effect of age at enrolment, age at follow-up, family history of prostate cancer, prostate enlargement and seasonality on prostate-specific antigen (PSA) estimated through log-normal mixed-effects modeling in an Italian cohort of healthy, 45- to 65-year-old subjects over a 4-year period. The median ratio was used as the measure of effect. Median and mean baseline PSA were 0.78 (interquartile range: 0.41-1.50) and 1.27 (95% CI: 1.19-1.35) ng/mL, respectively. A similar median annual increase of 5.7% (95% CI: 4.8%-6.5%) was found for age at enrolment and age at follow-up. Individuals with moderate to severe prostate enlargement had a median PSA ratio of 1.040 (95% CI: 0.919-1.176) and 1.318 (95% CI: 1.128-1.539), respectively. Median ratios of 1.200 (95% CI: 0.026-1.404) and 1.300 (95% CI: 0.915-1.845), respectively, were computed for subjects with only one or more than one prostate-cancer-affected relatives. Regarding seasonality, the highest value was shown in summertime, the lowest in wintertime, and the resulting median ratio was 1.280 (95% CI: 1.117-1.468). Irrespective of age, baseline PSA was in most cases about 1.00 ng/mL with a yearly median variation of about 5% over a 4-year period. Indeed, prostate enlargement, prostate cancer family history and seasonality showed a remarkable impact on PSA measurement. This should be considered when counseling patients with a PSA history.

AB - We assessed the joint effect of age at enrolment, age at follow-up, family history of prostate cancer, prostate enlargement and seasonality on prostate-specific antigen (PSA) estimated through log-normal mixed-effects modeling in an Italian cohort of healthy, 45- to 65-year-old subjects over a 4-year period. The median ratio was used as the measure of effect. Median and mean baseline PSA were 0.78 (interquartile range: 0.41-1.50) and 1.27 (95% CI: 1.19-1.35) ng/mL, respectively. A similar median annual increase of 5.7% (95% CI: 4.8%-6.5%) was found for age at enrolment and age at follow-up. Individuals with moderate to severe prostate enlargement had a median PSA ratio of 1.040 (95% CI: 0.919-1.176) and 1.318 (95% CI: 1.128-1.539), respectively. Median ratios of 1.200 (95% CI: 0.026-1.404) and 1.300 (95% CI: 0.915-1.845), respectively, were computed for subjects with only one or more than one prostate-cancer-affected relatives. Regarding seasonality, the highest value was shown in summertime, the lowest in wintertime, and the resulting median ratio was 1.280 (95% CI: 1.117-1.468). Irrespective of age, baseline PSA was in most cases about 1.00 ng/mL with a yearly median variation of about 5% over a 4-year period. Indeed, prostate enlargement, prostate cancer family history and seasonality showed a remarkable impact on PSA measurement. This should be considered when counseling patients with a PSA history.

KW - Age

KW - Longitudinal study

KW - Mixed-effects model

KW - Normality

KW - Prostate cancer

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=79959304245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959304245&partnerID=8YFLogxK

U2 - 10.5301/JBM.2011.8316

DO - 10.5301/JBM.2011.8316

M3 - Article

C2 - 21574152

AN - SCOPUS:79959304245

VL - 26

SP - 102

EP - 107

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 2

ER -